Dimerix Past Earnings Performance
Past criteria checks 0/6
Dimerix's earnings have been declining at an average annual rate of -30.9%, while the Biotechs industry saw earnings growing at 12.8% annually. Revenues have been growing at an average rate of 40.6% per year.
Key information
-30.9%
Earnings growth rate
-13.1%
EPS growth rate
Biotechs Industry Growth | 9.6% |
Revenue growth rate | 40.6% |
Return on equity | -632.9% |
Net Margin | -119.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Dimerix (ASX:DXB) Using Too Much Debt?
Dec 19We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate
Jul 05Can Dimerix (ASX:DXB) Afford To Invest In Growth?
Feb 17We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate
Sep 16We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate
Jun 02Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation
Sep 20Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?
May 17Here's What We Think About Dimerix's (ASX:DXB) CEO Pay
Feb 01Revenue & Expenses BreakdownBeta
How Dimerix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 9 | -11 | 3 | 17 |
30 Sep 23 | 9 | -12 | 3 | 19 |
30 Jun 23 | 9 | -14 | 2 | 20 |
31 Mar 23 | 8 | -14 | 2 | 19 |
31 Dec 22 | 6 | -14 | 2 | 18 |
30 Sep 22 | 6 | -12 | 2 | 16 |
30 Jun 22 | 6 | -10 | 3 | 14 |
31 Mar 22 | 5 | -10 | 2 | 13 |
31 Dec 21 | 4 | -9 | 2 | 11 |
30 Sep 21 | 4 | -7 | 2 | 10 |
30 Jun 21 | 4 | -6 | 2 | 9 |
31 Mar 21 | 3 | -6 | 1 | 8 |
31 Dec 20 | 2 | -6 | 1 | 7 |
30 Sep 20 | 2 | -5 | 1 | 6 |
30 Jun 20 | 2 | -4 | 1 | 6 |
31 Mar 20 | 2 | -4 | 1 | 5 |
31 Dec 19 | 1 | -4 | 1 | 4 |
30 Sep 19 | 1 | -4 | 1 | 3 |
30 Jun 19 | 1 | -3 | 1 | 3 |
31 Mar 19 | 1 | -3 | 1 | 3 |
31 Dec 18 | 1 | -3 | 1 | 3 |
30 Sep 18 | 1 | -3 | 2 | 3 |
30 Jun 18 | 1 | -3 | 2 | 2 |
31 Mar 18 | 1 | -3 | 2 | 2 |
31 Dec 17 | 1 | -3 | 2 | 1 |
30 Sep 17 | 1 | -2 | 2 | 1 |
30 Jun 17 | 1 | -2 | 1 | 1 |
31 Mar 17 | 1 | -2 | 1 | 1 |
31 Dec 16 | 1 | -2 | 1 | 1 |
30 Sep 16 | 1 | -3 | 1 | 1 |
30 Jun 16 | 1 | -5 | 1 | 1 |
31 Mar 16 | 0 | -5 | 1 | 0 |
31 Dec 15 | 0 | -5 | 1 | 0 |
30 Sep 15 | 0 | -3 | 1 | 0 |
30 Jun 15 | 0 | -1 | 1 | 0 |
30 Apr 14 | 0 | 0 | 0 | 0 |
30 Jun 13 | 0 | 0 | 0 | 0 |
Quality Earnings: DXB is currently unprofitable.
Growing Profit Margin: DXB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DXB is unprofitable, and losses have increased over the past 5 years at a rate of 30.9% per year.
Accelerating Growth: Unable to compare DXB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DXB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.6%).
Return on Equity
High ROE: DXB has a negative Return on Equity (-632.92%), as it is currently unprofitable.